Aurobindo Pharma Limited (AUROPHARMA.BO)
INR 1096.8
(0.16%)
INR 1096.8
(0.16%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 3.69 Billion INR | -58.5% |
| 2022 | 8.89 Billion INR | 200.72% |
| 2021 | -8.83 Billion INR | -2469.21% |
| 2020 | -343.9 Million INR | -100.97% |
| 2019 | 35.37 Billion INR | -30.79% |
| 2018 | 51.11 Billion INR | 42.97% |
| 2017 | 35.75 Billion INR | 24.3% |
| 2016 | 28.76 Billion INR | -32.36% |
| 2015 | 42.52 Billion INR | 7.49% |
| 2014 | 39.55 Billion INR | 10.15% |
| 2013 | 35.91 Billion INR | 11.29% |
| 2012 | 32.27 Billion INR | 6.66% |
| 2011 | 30.25 Billion INR | 35.8% |
| 2010 | 22.28 Billion INR | 7.03% |
| 2009 | 20.81 Billion INR | -6.1% |
| 2008 | 22.16 Billion INR | 35.49% |
| 2007 | 16.36 Billion INR | 8.91% |
| 2006 | 15.02 Billion INR | 27.65% |
| 2005 | 11.76 Billion INR | 20.75% |
| 2004 | 9.74 Billion INR | 28.1% |
| 2003 | 7.6 Billion INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q1 | - INR | -100.0% |
| 2023 Q2 | 25.16 Billion INR | 0.0% |
| 2023 Q4 | 3.69 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 FY | 3.69 Billion INR | -58.5% |
| 2022 FY | 8.89 Billion INR | 200.72% |
| 2022 Q1 | - INR | 100.0% |
| 2022 Q2 | 7.29 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q4 | 8.89 Billion INR | 0.0% |
| 2021 Q4 | -8.83 Billion INR | 0.0% |
| 2021 FY | -8.83 Billion INR | -2469.21% |
| 2021 Q2 | 2.91 Billion INR | 0.0% |
| 2021 Q1 | - INR | 100.0% |
| 2021 Q3 | - INR | -100.0% |
| 2020 Q4 | -343.9 Million INR | 0.0% |
| 2020 FY | -343.9 Million INR | -100.97% |
| 2020 Q2 | 18.46 Billion INR | 0.0% |
| 2019 Q2 | 40.15 Billion INR | 0.0% |
| 2019 FY | 35.37 Billion INR | -30.79% |
| 2019 Q4 | 35.37 Billion INR | 0.0% |
| 2018 FY | 51.11 Billion INR | 42.97% |
| 2018 Q2 | 38.01 Billion INR | 0.0% |
| 2018 Q4 | 51.11 Billion INR | 0.0% |
| 2017 Q4 | 35.75 Billion INR | 0.0% |
| 2017 FY | 35.75 Billion INR | 24.3% |
| 2017 Q2 | 38.65 Billion INR | 0.0% |
| 2016 FY | 28.76 Billion INR | -32.36% |
| 2016 Q2 | 32.29 Billion INR | 0.0% |
| 2016 Q4 | 28.76 Billion INR | 0.0% |
| 2015 Q2 | 35.73 Billion INR | 0.0% |
| 2015 Q4 | 42.52 Billion INR | 0.0% |
| 2015 FY | 42.52 Billion INR | 7.49% |
| 2014 Q2 | 26.24 Billion INR | 0.0% |
| 2014 Q4 | 39.55 Billion INR | 0.0% |
| 2014 FY | 39.55 Billion INR | 10.15% |
| 2013 Q2 | 31.99 Billion INR | 0.0% |
| 2013 Q4 | 35.91 Billion INR | 0.0% |
| 2013 FY | 35.91 Billion INR | 11.29% |
| 2012 Q4 | 32.27 Billion INR | 0.0% |
| 2012 FY | 32.27 Billion INR | 6.66% |
| 2011 Q4 | 30.25 Billion INR | 0.0% |
| 2011 FY | 30.25 Billion INR | 35.8% |
| 2010 FY | 22.28 Billion INR | 7.03% |
| 2009 FY | 20.81 Billion INR | -6.1% |
| 2008 FY | 22.16 Billion INR | 35.49% |
| 2007 FY | 16.36 Billion INR | 8.91% |
| 2006 FY | 15.02 Billion INR | 27.65% |
| 2005 FY | 11.76 Billion INR | 20.75% |
| 2004 FY | 9.74 Billion INR | 28.1% |
| 2003 FY | 7.6 Billion INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 3.86 Billion INR | 4.465% |
| Glenmark Life Sciences Limited | -2.84 Billion INR | 229.924% |
| Granules India Limited | 9.28 Billion INR | 60.231% |
| Indoco Remedies Limited | 6.47 Billion INR | 42.972% |
| Achyut Healthcare Limited | -3.74 Million INR | 98693.166% |
| Ajanta Pharma Limited | -954.9 Million INR | 486.773% |
| Alkem Laboratories Limited | -1.6 Billion INR | 329.483% |
| Alpa Laboratories Limited | 35.36 Million INR | -10343.967% |
| Brooks Laboratories Limited | 49.48 Million INR | -7363.474% |
| AstraZeneca Pharma India Limited | -5.01 Billion INR | 173.683% |
| Bajaj HealthCare Limited | 3.29 Billion INR | -11.954% |
| Bliss GVS Pharma Limited | -1.15 Billion INR | 419.006% |
| Dr. Reddy's Laboratories Limited | 12.91 Billion INR | 71.399% |
| Eris Lifesciences Limited | 13.8 Billion INR | 73.249% |
| FDC Limited | -57.75 Million INR | 6495.103% |
| Glenmark Pharmaceuticals Limited | -4.28 Billion INR | 186.186% |
| Gufic Biosciences Limited | 3.19 Billion INR | -15.621% |
| Ind-Swift Laboratories Limited | -4.15 Billion INR | 188.93% |
| Ipca Laboratories Limited | 11.41 Billion INR | 67.646% |
| Jagsonpal Pharmaceuticals Limited | -1.38 Billion INR | 365.718% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | -91.074% |
| Lasa Supergenerics Limited | 205.79 Million INR | -1694.615% |
| Laurus Labs Limited | 24.38 Billion INR | 84.854% |
| Lupin Limited | 17.19 Billion INR | 78.518% |
| Mankind Pharma Limited | -9.9 Billion INR | 137.276% |
| Medicamen Biotech Limited | 160.31 Million INR | -2203.763% |
| Medico Remedies Limited | 78.67 Million INR | -4594.256% |
| Megasoft Limited | 1.28 Billion INR | -187.293% |
| NATCO Pharma Limited | -5.81 Billion INR | 163.491% |
| Piramal Pharma Limited | 42.27 Billion INR | 91.264% |
| RPG Life Sciences Limited | -364.7 Million INR | 1112.695% |
| Sigachi Industries Limited | 859.94 Million INR | -329.479% |
| Sun Pharmaceutical Industries Limited | -72.47 Billion INR | 105.096% |
| Suven Pharmaceuticals Limited | 144.97 Million INR | -2447.525% |
| Syncom Formulations (India) Limited | 46.21 Million INR | -7892.253% |
| Unichem Laboratories Limited | 931.91 Million INR | -296.313% |
| Wanbury Limited | 1.1 Billion INR | -233.971% |
| Windlas Biotech Limited | -273.04 Million INR | 1452.659% |
| ZIM Laboratories Limited | 983.6 Million INR | -275.486% |
| Zydus Lifesciences Limited | 3.91 Billion INR | 5.59% |
| Sun Pharma Advanced Research Company Limited | -941.8 Million INR | 492.153% |
| Divi's Laboratories Limited | -39.77 Billion INR | 109.287% |
| Hester Biosciences Limited | 2.29 Billion INR | -61.227% |
| Procter & Gamble Health Limited | -2.34 Billion INR | 257.296% |
| Amrutanjan Health Care Limited | -248.79 Million INR | 1584.493% |
| Bal Pharma Limited | 1.26 Billion INR | -192.293% |
| Strides Pharma Science Limited | 23.25 Billion INR | 84.12% |
| Venus Remedies Limited | -267.7 Million INR | 1479.641% |
| Aarti Pharmalabs Limited | 2.61 Billion INR | -41.403% |
| Nectar Lifesciences Limited | 6.15 Billion INR | 40.018% |
| Shilpa Medicare Limited | 9.06 Billion INR | 59.278% |
| Aarti Drugs Limited | 5.54 Billion INR | 33.435% |
| IOL Chemicals and Pharmaceuticals Limited | -1.1 Billion INR | 435.358% |
| Suven Life Sciences Limited | -1.63 Billion INR | 326.208% |
| Ind-Swift Limited | 9.5 Billion INR | 61.158% |
| Valiant Laboratories Limited | -295.03 Million INR | 1351.83% |
| J. B. Chemicals & Pharmaceuticals Limited | 2.82 Billion INR | -30.912% |
| Solara Active Pharma Sciences Limited | 10.02 Billion INR | 63.174% |
| Themis Medicare Limited | 764.96 Million INR | -382.808% |
| Hikal Limited | 7.96 Billion INR | 53.643% |
| Torrent Pharmaceuticals Limited | 31.83 Billion INR | 88.397% |
| Sequent Scientific Limited | 4.17 Billion INR | 11.615% |
| Novartis India Limited | -5.89 Billion INR | 162.693% |
| Wockhardt Limited | 18.27 Billion INR | 79.785% |
| Jubilant Pharmova Limited | 27.07 Billion INR | 86.357% |
| Biofil Chemicals and Pharmaceuticals Limited | -18.44 Million INR | 20122.227% |
| Neuland Laboratories Limited | -214.05 Million INR | 1825.373% |
| Morepen Laboratories Limited | -231.17 Million INR | 1697.628% |
| Kilitch Drugs (India) Limited | 120.03 Million INR | -2976.75% |
| Mangalam Drugs & Organics Limited | 975.81 Million INR | -278.485% |